Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
AB Sciex
RANDOX LABORATORIES

Graft-Versus-Host Disease Biomarker Identified

By Labmedica International staff writers
Posted on 19 Aug 2013
Image: Histopathology of graft-versus-host disease (Photo courtesy of Dr. Ed Friedlander).
Image: Histopathology of graft-versus-host disease (Photo courtesy of Dr. Ed Friedlander).
A biomarker accessible in blood tests could be used to predict which stem cell transplant patients are at highest risk for a potentially fatal immune response called graft-versus-host disease (GVHD).

Allogeneic transplants are used to treat blood and bone marrow cancers such as leukemia and multiple myeloma, often as a last resort as GVHD can occur when immune cells from the transplant see the patient's body as foreign and attack it.

Scientists, collaborating with the Indiana University Melvin and Bren Simon Cancer Center (Indianapolis, IN, USA), collected plasma samples prospectively between 2000 and 2010 from patients who underwent allogeneic hematopoietic stem-cell transplantation. They compared 12 biomarkers in plasma obtained a median of 16 days after therapy initiation from 10 patients with a complete response by day 28 after therapy initiation and in plasma obtained from 10 patients with progressive GVHD during therapy.

The lead biomarker, suppression of tumorigenicity 2 (ST2), was measured at the beginning of treatment for GVHD in plasma from 381 patients and during the first month after transplantation in three independent sets totaling 673 patients to determine the association of this biomarker with treatment-resistant GVHD and 6-month mortality after treatment or transplantation. The investigators found that patients with a high level of the protein ST2 were more than twice as likely to have graft-versus-host disease that resisted standard treatment with steroids, and nearly four times as likely to die within six months of the transplant.

Sophie Paczesny, MD, PhD, a senior author of the study, said, “What we found particularly significant was that this marker was a better predictor than the clinical severity of the disease when it was diagnosed. This blood test, which is currently available to clinicians, will make informed treatment possible as the clinicians will now be able to adjust therapy to the degree of risk rather than treating every patient the same way.”

The authors concluded that early identification of patients who are unlikely to respond to standard treatments is important and would allow physicians to consider additional therapies and early intervention. On the other hand, patients with low risk will not need to have additional medicine further suppressing their immune system. However, they cautioned that additional large prospective studies are needed to better define the levels of risk predicted by the ST2 marker. The study was published on August 8, 2013, in the New England Journal of Medicine (NEJM).

Related Links:

Indiana University Melvin and Bren Simon Cancer Center


VIRCELL
DiagCor Bioscience
ADVANCED INSTRUMENTS
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.